Ipsen 관리

관리 기준 확인 4/4

Ipsen CEO는 David Loew, Jul2020 에 임명되었습니다 의 임기는 4.33 년입니다. 총 연간 보상은 € 4.36M, 22.6% 로 구성됩니다. 22.6% 급여 및 77.4% 보너스(회사 주식 및 옵션 포함). 는 $ 5.70M 가치에 해당하는 회사 주식의 0.061% 직접 소유합니다. 5.70M. 경영진과 이사회의 평균 재임 기간은 각각 5.5 년과 11 년입니다.

주요 정보

David Loew

최고 경영자

€4.4m

총 보상

CEO 급여 비율	22.6%
CEO 임기	4.3yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	5.5yrs
이사회 평균 재임 기간	11yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Loew 의 보수는 Ipsen 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

보상 대 시장: David 의 총 보상 ($USD 4.57M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 7.94M ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Loew (57 yo)

4.3yrs

테뉴어

€4,361,753

보상

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Loew	MD, CEO & Director	4.3yrs	€4.36m	0.061% $ 5.7m
Aymeric Le Chatelier	Executive VP & CFO	10yrs	€1.02m	데이터 없음
Aidan Murphy	Executive VP and Head of Technical Operations	6.8yrs	데이터 없음	데이터 없음
Craig Marks	Vice-President of Investor Relations	no data	데이터 없음	데이터 없음
Francois Garnier	Executive VP of Legal Affairs	9.9yrs	데이터 없음	데이터 없음
Regis Mulot	Executive VP & Chief Human Resources Officer	6.7yrs	데이터 없음	데이터 없음
Dominique Bery	Head of Nordics & Baltics	7.6yrs	데이터 없음	데이터 없음
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	4.2yrs	데이터 없음	데이터 없음
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	4.1yrs	데이터 없음	데이터 없음
James Levine	President of Fondation Ipsen	no data	데이터 없음	데이터 없음
Mari Scheiffele	Executive VP & President of International	3yrs	데이터 없음	데이터 없음
Catherine Abi-Habib	Executive VP and Head of Strategy & Transformation	2.7yrs	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: IPSE.Y 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Loew	MD, CEO & Director	4.5yrs	€4.36m	0.061% $ 5.7m
Marc M. de Garidel	Non-Executive Chairman	14yrs	€600.00k	0.17% $ 15.6m
Margaret Liu	Independent Director	7.4yrs	€130.00k	0.00084% $ 77.9k
Michèle Ollier	Director	9.5yrs	€65.00k	0.00061% $ 56.6k
Karen Witts	Independent Director	2.8yrs	€115.00k	0.00061% $ 56.6k
Antoine Flochel	Vice Chairman	19.3yrs	€165.00k	0.0037% $ 338.4k
Henri Beaufour	Director	19.3yrs	€36.00k	0% $ 0
Anne Beaufour	Director	19.3yrs	€45.00k	26.54% $ 2.5b
Carol Xueref	Director	12.4yrs	€115.00k	0.00061% $ 56.6k
Philippe Bonhomme	Director	12.8yrs	€95.00k	데이터 없음
Piet Wigerinck	Independent Director	6.5yrs	€78.00k	0.00083% $ 77.0k
Laetitia Ducroquet	Employees Representative Director	4yrs	데이터 없음	0.0010% $ 93.6k

11.0yrs

평균 재임 기간

60.5yo

평균 연령

경험이 풍부한 이사회: IPSE.Y 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11 년).

Ipsen 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Ipsen Announces Executive Changes

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications

Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021

Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen Announces First Presentation of Results from the Pivotal Phase III CheckMate -9ER Trial

Ipsen Announces the Release of First Efficacy and Safety Data from the Clarinet Forte Study

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령